Tags

Type your tag names separated by a space and hit enter

[Pathophysiology, diagnosis and treatment of anemia].

Abstract

Anemia can result from deficient erythropoiesis [aplastic anemia, myelodysplastic syndromes (MDS), iron deficiency anemia, anemia of chronic disease (ACD), thalassemia, megaloblastic anemia, chronic renal failure, hematological malignancies, etc.], excessive RBC destruction [hereditary spherocytosis, inherited enzyme deficiency, hemoglobinopathies, autoimmune hemolytic anemia (AIHA), paroxysmal nocturnal hemoglobinuria (PNH), etc.], and blood loss. Based on the measured red cell size(MCV), anemia is classified as microcytic, normocytic, or macrocytic. Iron parameters (serum iron, serum ferritin, etc.), reticulocyte count, bone marrow examination, Coombs test, serum vitamin B12 level, and Ham test are also useful in the differential diagnosis of anemia. Novel treatment of anemia includes lenalidomide for 5q(-)MDS, azacitidine for high-risk MDS, and eculizumab for PNH. Oral iron chelator(deferasirox) developed for the treatment of transfusional iron overload is also very useful for the management of patients with bone marrow failure syndromes.

Links

Authors+Show Affiliations

Division of Hematology, Department of Medicine, Jichi Medical University.

Source

MeSH

Anemia
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Azacitidine
Benzoates
Deferasirox
Diagnosis, Differential
Hematopoietic Stem Cell Transplantation
Humans
Iron Chelating Agents
Lenalidomide
Thalidomide
Triazoles

Pub Type(s)

Journal Article
Review

Language

jpn

PubMed ID

18326312

Citation

Ozawa, Keiya. "[Pathophysiology, Diagnosis and Treatment of Anemia]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 66, no. 3, 2008, pp. 423-8.
Ozawa K. [Pathophysiology, diagnosis and treatment of anemia]. Nippon Rinsho. 2008;66(3):423-8.
Ozawa, K. (2008). [Pathophysiology, diagnosis and treatment of anemia]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 66(3), pp. 423-8.
Ozawa K. [Pathophysiology, Diagnosis and Treatment of Anemia]. Nippon Rinsho. 2008;66(3):423-8. PubMed PMID: 18326312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pathophysiology, diagnosis and treatment of anemia]. A1 - Ozawa,Keiya, PY - 2008/3/11/pubmed PY - 2008/4/23/medline PY - 2008/3/11/entrez SP - 423 EP - 8 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nippon Rinsho VL - 66 IS - 3 N2 - Anemia can result from deficient erythropoiesis [aplastic anemia, myelodysplastic syndromes (MDS), iron deficiency anemia, anemia of chronic disease (ACD), thalassemia, megaloblastic anemia, chronic renal failure, hematological malignancies, etc.], excessive RBC destruction [hereditary spherocytosis, inherited enzyme deficiency, hemoglobinopathies, autoimmune hemolytic anemia (AIHA), paroxysmal nocturnal hemoglobinuria (PNH), etc.], and blood loss. Based on the measured red cell size(MCV), anemia is classified as microcytic, normocytic, or macrocytic. Iron parameters (serum iron, serum ferritin, etc.), reticulocyte count, bone marrow examination, Coombs test, serum vitamin B12 level, and Ham test are also useful in the differential diagnosis of anemia. Novel treatment of anemia includes lenalidomide for 5q(-)MDS, azacitidine for high-risk MDS, and eculizumab for PNH. Oral iron chelator(deferasirox) developed for the treatment of transfusional iron overload is also very useful for the management of patients with bone marrow failure syndromes. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/18326312/[Pathophysiology_diagnosis_and_treatment_of_anemia]_ L2 - http://www.diseaseinfosearch.org/result/441 DB - PRIME DP - Unbound Medicine ER -